



With its innovative NEXUS™ Stent Graft System, Endospan has transformed treatment of life threatening Aortic Arch Disease from a high-risk open surgery into a minimally invasive aortic arch repair, including aneuysms and dissections.

o **URGENT CLINICAL NEED FOR ENDOVASCULAR AORTIC ARCH DISEASE REPAIR.** Aortic Arch Disease can manifest in two different forms, both equally deadly and difficult to treat. (1) An **aortic aneurysm** does not have symptoms. If the aortic aneurysm bursts, there is a sudden, severe pain, and an extreme drop in blood pressure. (2) **Aortic dissections** occur suddenly and usually without warning with symptoms of severe chest pain, loss of consciousness and paralysis similar to a stroke. Aortic Arch **aneuysms** over 5.5 cm in diameter require elective surgery to prevent emergent rupture. Aortic Arch **dissections** require an emergency procedure with mortality rate within 30 days reaching 30%. Unfortunately, many **Aortic Arch aneurysms and dissections** are either not diagnosed or misdiagnosed in emergency situations. Because the incidence of **Aortic Arch aneurysms and dissections** rises sharply in individuals over 60 years of age, the future prevalence of **Aortic Arch Disease** is expected to increase substantially in association with the aging population.

o **NEXUS IS THE 1ST OFF-THE-SHELF ENDOVASCULAR PRODUCT TO TREAT AORTIC ARCH DISEASE.** Endospan has initiated the CE-marking regulatory process to market in Europe the NEXUS Stent Graft System, the first off-the-shelf endovascular system to treat Aortic Arch Disease: a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation.

o **CE MARK REGISTRATION IS UNDERWAY.** The patented and revolutionary modular design of NEXUS excludes aneurysm and dissection while maintaining perfusion to the descending- and supra-aortic branches. NEXUS transforms a complex surgical aortic arch repair into a standard endovascular procedure. NEXUS is designed for enhanced intra-procedural and long-term stability attributable to its proprietary geometrical design, which reduces arch manipulation and, hence, stroke risks. NEXUS also is designed to reduce complications and post-op recovery time. Above all, NEXUS is designed to be beneficial to the vast number of patients for whom there is currently no minimally invasive Aortic Arch Disease treatment alternative.

o **SIGNIFICANTLY EXPANDABLE MARKET OPPORTUNITY AS ADJUNCTIVE HEART TREATMENT.** Currently, minimally invasive techniques are standard for descending aortic disease and heart disease. However, the bridge between the two in the aortic arch is vastly underserved and still a very invasive, high-mortality surgery. More than 120,000 patients suffer thoracic aortic arch disease every year in the USA and Europe, with only about 25% being diagnosed or treated. This global market opportunity is >\$1.3 billion in a high Average Selling Price (ASP) segment with no off-the-shelf competition. **The NEXUS technology has been de-risked and will bridge the unmet existing gap between the the heart and peripheral markets.**

CONTACTS & KEY INFORMATION

Domicile	Maskit St. 4 Herzlia Business Park Herzlia, ISRAEL 46733
Website	www.endospan.com
Investors	Accelmed, Haisco Pharmaceutical Group, Sequoia, Vitalife
Focus	Endovascular stent grafts for minimally invasive treatment of thoracic and abdominal aortic aneurysms and dissections
Innovation	Less invasive endovascular approach compared to high-risk open surgery
Endovascular Product Platform	NEXUS™ Stent Graft System for treating Thoracic Aortic Arch (TAA) disease; HORIZON™ Stent Graft System for treating Abdominal Aortic Aneurysm (AAA).
Regulatory	CE mark in process for NEXUS™

LEADERSHIP TEAM


Kevin Mayberry Chief Executive Officer
Yaniv Marmur Vice President, Research & Development
Ami Katz Vice President, Operations
Eli Gendler Chief Financial Officer
Orly Schwartz Manager, Clinical & Regulatory Affairs

CLINICAL ADVISORY BOARD


Ross Milner, MD Vascular Surgeon, University of Chicago
Mario Lachat, MD Vascular Surgeon, University of Zurich
David Planer, MD Interventional Cardiologist, Hebrew University, Israel
Daniel Silverberg, MD Vascular Surgeon, Sheba Medical Center, Israel
Thomas Lindsay, MD Vascular Surgeon, University of Toronto

Now, Treating Aortic Arch Disease Does Not Require Open-Heart Surgery

Aortic Arch Disease: Thoracic Aortic Aneurysm



Off-The-Shelf Endovascular Solution: NEXUS*



* CAUTION: NEXUS™ is approved for investigational use; CE mark registration is in process in Europe.